VEEV250117C340000
- 0.33
- 0.000.00%
Veeva Systems Newsroom
Veeva Systems Is Maintained at Overweight by Keybanc
Veeva Systems Analyst Ratings
KeyBanc Cuts Price Target on Veeva Systems to $255 From $285, Keeps Overweight Rating
KeyBanc Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $255
Morgan Stanley Maintains Veeva Systems(VEEV.US) With Sell Rating, Maintains Target Price $195
Piper Sandler Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $290
Piper Sandler Reaffirms Their Buy Rating on Veeva Systems (VEEV)
Wells Fargo Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $285
Stephens Initiates Veeva Systems(VEEV.US) With Buy Rating, Announces Target Price $280
Veeva Systems Analyst Ratings
Veeva Systems Is Maintained at Underweight by Morgan Stanley
Morgan Stanley Maintains Veeva Systems(VEEV.US) With Sell Rating, Raises Target Price to $195
Morgan Stanley Sticks to Its Sell Rating for Veeva Systems (VEEV)
Veeva Systems Analyst Ratings
JP Morgan Maintains Neutral on Veeva Systems, Raises Price Target to $218
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Conmed (CNMD) and Veeva Systems (VEEV)
Morgan Stanley Maintains Veeva Systems(VEEV.US) With Sell Rating, Maintains Target Price $183
Customer attrition has led to a decline in Veeva (VEEV.US) stock prices. Baird reassures the market: the financial impact is manageable and maintains a "Shareholding" rating.
Truist Financial Keeps Their Hold Rating on Veeva Systems (VEEV)
Truist Financial Maintains Veeva Systems(VEEV.US) With Hold Rating, Maintains Target Price $261